FDA Approves First Biosimilar for Non-Hodgkin Lymphoma

November 28, 2018 – The FDA has approved the first rituximab biosimilar, CT-P10 (rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy. This is the first biosimilar approved by the FDA for the treatment of patients with NHL. CT-P10, which is developed by Celltrion and Teva Pharmaceutical Industries, has approved indications that are … (leggi tutto)